Ann: Coviu and ResApp Health Sign Service Agreement, page-179

First 179 Last

Share
Profile

Follow
AlCp

26,416 Posts.

1717

10/07/20

17:53

Post #: 45786936
Share

Originally posted by Diamo ↑

As a RSH shareholder I do follow RAP’s progress into their commercialisation strategy as both companies cater for respiratory ailments.

RAP’s App is a diagnostic tool - RSH’s device a monitoring tool. Both have their advantages and do compliment each other!
I hope your approach to launch is the correct one as RSH will benefit greatly with monitoring Asthma after being diagnosed by RAP as such.
So if you don’t mind I keep on following your progression and make the occasional remark about it.

IMHO your positives are the affordable costs involved for your App’s. But both App’s will need the backing of clinicians and ongoing advertising campaigns to see proper financial rewards. Just to rely on income from Telehealth and AppStore won’t do!
At RSH it has taken us many years to gather together a team whose focus is the participation of the medical and pharmaceutical fraternity. Only with this backing will RSH launch its device later in the year.

So I do hope you will have success in the respiratory field, as your success will be ours as well!

Cheers

Expand

Also the telehealth market is huge in Europe and DTC for a OSA screening product can globally bring in a few million revenue so I'm not sure what you mean???? RAP is also doing evaluation and pilot test at clinic and hospital.....I thought the pharmacies wanted clinical studies for Wheezo to be tested against the current physician standard before committing since the got regulatory approved was with clinical data tested against just a stethoscope and this clinical study was meant to be completed early this year, where is this clinical study results?

RAP Price at posting: 14.0¢ Sentiment: Buy Disclosure: Held
4 Upvote

0 Great analysis

Reply